ZEALAND PHARMA A/S DK 1/ DK0060257814 /
16/05/2024 13:13:28 | Chg. -3.600 | Volume | Bid13:36:10 | Ask13:36:10 | High | Low |
---|---|---|---|---|---|---|
83.600EUR | -4.13% | - Turnover: - |
83.850Bid Size: 400 | 84.350Ask Size: 400 | 87.200 | 82.750 |
GlobeNewswire
09/05
Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial...
GlobeNewswire
20/03
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatm...
GlobeNewswire
26/02
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated ...
GlobeNewswire
26/02
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver dise...
GlobeNewswire
20/02
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financia...
GlobeNewswire
08/01
Zealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billion
GlobeNewswire
02/01
Zealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on Janua...
GlobeNewswire
23/12/2023
U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyp...
GlobeNewswire
22/12/2023
Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
GlobeNewswire
22/12/2023
Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank
GlobeNewswire
30/11/2023
Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers
GlobeNewswire
09/11/2023
Zealand Pharma Announces Financial Results for the First Nine Months of 2023
GlobeNewswire
07/11/2023
Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023